RMB Capital Management LLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 8.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,960 shares of the company’s stock after purchasing an additional 687 shares during the quarter. RMB Capital Management LLC’s holdings in AstraZeneca were worth $594,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth about $195,000. Yousif Capital Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth about $2,810,000. CWM LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth about $472,000. Oppenheimer & Co. Inc. boosted its stake in shares of AstraZeneca by 2.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 12,399 shares of the company’s stock worth $722,000 after acquiring an additional 295 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of AstraZeneca by 13,322.8% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 80,000 shares of the company’s stock worth $4,628,000 after acquiring an additional 79,404 shares in the last quarter. Hedge funds and other institutional investors own 20.46% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the company. Citigroup boosted their price objective on AstraZeneca from £105 ($128.66) to £130 ($159.29) in a research report on Tuesday, July 12th. Danske assumed coverage on AstraZeneca in a research report on Tuesday, May 24th. They set a “buy” rating for the company. Kepler Capital Markets cut AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Credit Suisse Group boosted their price objective on AstraZeneca from GBX 9,000 ($110.28) to £110 ($134.79) in a research report on Friday, April 8th. Finally, Barclays boosted their price objective on AstraZeneca from £115 ($140.91) to £120 ($147.04) in a research report on Thursday, April 14th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8,840.50.
AstraZeneca Trading Down 0.4 %
AstraZeneca Cuts Dividend
The company also recently declared a semi-annual dividend, which will be paid on Monday, September 12th. Shareholders of record on Friday, August 12th will be issued a $0.465 dividend. The ex-dividend date is Thursday, August 11th. This represents a yield of 2.2%. AstraZeneca’s dividend payout ratio (DPR) is -470.72%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.